Esaxerenone

Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

Retrieved on: 
Thursday, December 8, 2022

With the initial dose-escalation results now in hand, I am excited to explore further in the QUARTZ-101 trial how XL102 may benefit patients with advanced solid tumors who have exhausted treatment options.

Key Points: 
  • With the initial dose-escalation results now in hand, I am excited to explore further in the QUARTZ-101 trial how XL102 may benefit patients with advanced solid tumors who have exhausted treatment options.
  • QUARTZ-101 is enrolling patients with solid tumors that are confirmed to be inoperable, locally advanced, metastatic or recurrent.
  • The most common types of cancer for patients enrolled were hormone receptor-positive breast cancer (n=12), pancreatic cancer (n=3) and sarcoma (n=3).
  • Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.

Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022

Retrieved on: 
Wednesday, November 30, 2022

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the virtual JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022 at 12:00 pm ET / 9:00 am PT.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the virtual JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022 at 12:00 pm ET / 9:00 am PT.
  • To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.
  • Exelixis is a member of the Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Retrieved on: 
Thursday, November 10, 2022

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the companys management team will participate in fireside chats at the following investor conferences in November:

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the companys management team will participate in fireside chats at the following investor conferences in November:
    Stifel 2022 Healthcare Conference: Exelixis is scheduled to present at 9:45 a.m.
  • Jefferies London Healthcare Conference 2022: Exelixis is scheduled to present at 9:45 a.m. GMT / 4:45 a.m.
  • Piper Sandler 34th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline

Retrieved on: 
Thursday, November 3, 2022

In September 2020, Exelixis and Catalent entered into a separate agreement under which Catalent is applying its SMARTag bioconjugation platform to build ADCs using monoclonal antibodies from Exelixis growing preclinical pipeline.

Key Points: 
  • In September 2020, Exelixis and Catalent entered into a separate agreement under which Catalent is applying its SMARTag bioconjugation platform to build ADCs using monoclonal antibodies from Exelixis growing preclinical pipeline.
  • Exelixis will fund the development work conducted by Catalent until development candidate selection is complete, after which Exelixis will assume responsibility for conducting preclinical, clinical, and commercial activities.
  • We expect the new license agreement with Exelixis will yield innovative and differentiated therapies with the potential to improve care and outcomes for cancer patients.
  • Catalent and SMARTag are registered trademarks of Catalent Pharma Solutions, Inc., or its subsidiaries in the U.S. or other countries.

Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα

Retrieved on: 
Tuesday, November 1, 2022

Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRP.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRP.
  • With an Investigational New Drug filing anticipated in the first quarter of 2023, this agreement provides an exciting opportunity to expand our clinical pipeline.
  • Sairopa was founded to develop a portfolio of therapeutic antibodies that modulate immune system activity to provide benefit to cancer patients.
  • Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.

Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan

Retrieved on: 
Tuesday, November 1, 2022

Exelixis, Inc. (Nasdaq: EXEL) and Cybrexa Therapeutics (Cybrexa) today announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12 (alphalex exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) that utilizes Cybrexas proprietary alphalex technology to enhance delivery of exatecan to tumor cells.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and Cybrexa Therapeutics (Cybrexa) today announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12 (alphalex exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) that utilizes Cybrexas proprietary alphalex technology to enhance delivery of exatecan to tumor cells.
  • This collaboration underscores Exelixis commitment to expanding its clinical pipeline building upon its biotherapeutics and targeted drug therapy expertise.
  • "This agreement aligns with Exelixis goal of acquiring first- or best-in-class clinical-stage assets that may provide differentiated benefits to patients with cancer.
  • Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.

Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 1, 2022

In the third quarter of 2022, global cabozantinib franchise net product revenues generated by Exelixis and its partners were almost $500 million.

Key Points: 
  • In the third quarter of 2022, global cabozantinib franchise net product revenues generated by Exelixis and its partners were almost $500 million.
  • Exelixis earned $30.3 million in royalty revenues during the quarter ended September 30, 2022, pursuant to collaboration agreements with its partners, Ipsen and Takeda.
  • Previously, in July, Exelixis announced that COSMIC-313 met its primary endpoint, demonstrating significant improvement in PFS at the primary analysis.
  • Exelixis management will discuss the companys financial results for the third quarter of 2022 and provide a general business update during a conference call beginning at 5:00 p.m.

Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022

Retrieved on: 
Tuesday, October 18, 2022

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close.
  • ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.

Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial

Retrieved on: 
Tuesday, October 4, 2022

The novel triplet combination of XL092 and the fixed-dose combination of nivolumab and relatlimab has the potential to be used in multiple expansion cohorts.

Key Points: 
  • The novel triplet combination of XL092 and the fixed-dose combination of nivolumab and relatlimab has the potential to be used in multiple expansion cohorts.
  • XL092 is Exelixis next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancers growth and spread.
  • Bristol Myers Squibbs relatlimab is a lymphocyte activation gene-3 (LAG-3)-blocking antibody.
  • The dose-escalation stage will determine the recommended dose in patients with advanced solid tumors for each of the combination therapy regimens, including XL092 and nivolumab, XL092, nivolumab and ipilimumab, and XL092 and the fixed-dose combination of nivolumab and relatlimab.

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September

Retrieved on: 
Tuesday, September 6, 2022

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the companys management team will participate in fireside chats at the following investor conferences in September:

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the companys management team will participate in fireside chats at the following investor conferences in September:
    Morgan Stanley 20th Annual Global Healthcare Conference: Exelixis is scheduled to present at 4:05 p.m.
  • BofA Securities Global Healthcare Conference 2022: Exelixis is scheduled to present at 2:10 p.m. BST / 9:10 a.m.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.